Details for New Drug Application (NDA): 218371
✉ Email this page to a colleague
The generic ingredient in HALOPERIDOL is haloperidol decanoate. There are twenty drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the haloperidol decanoate profile page.
Summary for 218371
Tradename: | HALOPERIDOL |
Applicant: | Rubicon |
Ingredient: | haloperidol lactate |
Patents: | 0 |
Suppliers and Packaging for NDA: 218371
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
HALOPERIDOL | haloperidol lactate | CONCENTRATE;ORAL | 218371 | ANDA | Advagen Pharma Ltd | 72888-173 | 72888-173-47 | 15 mL in 1 BOTTLE (72888-173-47) |
HALOPERIDOL | haloperidol lactate | CONCENTRATE;ORAL | 218371 | ANDA | Advagen Pharma Ltd | 72888-173 | 72888-173-48 | 120 mL in 1 BOTTLE (72888-173-48) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | CONCENTRATE;ORAL | Strength | EQ 2MG BASE/ML | ||||
Approval Date: | Jan 31, 2024 | TE: | AA | RLD: | No |
Complete Access Available with Subscription